covid
Buscar en
Endocrinología y Nutrición
Toda la web
Inicio Endocrinología y Nutrición Acromegalia, hiperparatiroidismo primario y feocromocitoma
Información de la revista
Vol. 53. Núm. 6.
Páginas 382-386 (junio 2006)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 53. Núm. 6.
Páginas 382-386 (junio 2006)
Notas clínicas
Acceso a texto completo
Acromegalia, hiperparatiroidismo primario y feocromocitoma
Acromegaly, primary hyperparathyroidism and pheochromocytoma
Visitas
8294
Arturo Lisbona Gila,
, Mercedes Robledob, Asís Fernández Riestrac, César Alonso Rodrígueza
a Servicio de Endocrinología y Nutrición. Hospital Central de la Defensa. Madrid. España
b Servicio de Genética de Tumores Endocrinos. Centro Nacional de Investigaciones Oncológicas. Madrid. España
c Servicio de Medicina Interna. Hospital Central de la Defensa. Madrid. España
Este artículo ha recibido
Información del artículo
Resumen
Bibliografía
Descargar PDF
Estadísticas

Se presenta el caso de una mujer que 5 años después de haber sido diagnosticada de feocromocitoma adrenal derecho e hiperparatiroidismo primario, desarrolló una acromegalia por adenoma hipofisario. Se descartó la existencia de carcinoma medular de tiroides y de mutación germinal en RET y en VHL. La determinación del gen MEN-1 también resultó negativa. Se dan en este caso la existencia de un tumor característico de la NEM-2 como el feocromocitoma, otro característico de la NEM-1 como el adenoma hipofisario secretor de GH e hiperparatiroidismo primario, que se da en ambas neoplasias endocrinas múltiples, pero sin mutaciones germinales en RET, VHL y MEN-1.

Palabras clave:
Feocromocitoma
Acromegalia
Hiperparatiroidismo primario
NEM-1
NEM-2

We present the case of a 56-year-old woman who, 5 years after receiving a diagnosis of unilateral adrenal pheochromocytoma and primary hyperparathyroidism, was diagnosed with acromegaly caused by a growth hormonesecreting pituitary adenoma. No germ-line mutations in RET, VHL and MEN-1 gene were detected. Medullar thyroid carcinoma was also ruled out. Therefore, the present case shows coexistence of a tumor characteristic of MEN 2 syndrome (pheochromocytoma) with a growth hormone-secreting pituitary tumor characteristic of MEN 1 syndrome and primary hyperparathyroidism, which can be observed in both multiple endocrine neoplasia syndromes, but without germline mutations in RET, VHL and MEN-1.

Key words:
Pheochromocytoma
Acromegaly
Primary hyperparathyroidism
MEN-1
MEN-2
El Texto completo está disponible en PDF
Bibliografía
[1.]
A. Calender.
Molecular genetics of neuroendocrine tumors.
Digestion, 62 (2000), pp. 3-38
[2.]
T.M. Shattuck, S. Välimäki, T. Obara, R.D. Gaz, O.H. Clark, D. Shoback, et al.
Somatic and germ-line mutations of the HRPT2 in sporadic parathyroid carcinoma.
N Engl J Med, 349 (2003), pp. 1722-1729
[3.]
J.R. Zeller, H.M. Kauffman, R.A. Komorowski, H.D. Itskovitz.
Bilateral pheochromocytoma and islet cell adenoma of the pancreas.
Arch Surg, 117 (1982), pp. 827-830
[4.]
J.A. Carney, V.L. Go, H. Gordon, R.C. Northcutt, A.G. Pearse, S.G. Sheps.
Familial pheochromocitoma and islet cell tumor of the pancreas.
Am J Med, 68 (1980), pp. 515-521
[5.]
R. Tateishi, A. Wada, S. Ishiguro, M. Ehara, H. Sakamoto, T. Miki, et al.
Coexistence of bilateral pheochromocytoma and pancreatic islet cell tumor: report of a case and review of the literature.
Cancer, 42 (1978), pp. 2928-2934
[6.]
G.L. Miller, J. Wynn.
Acromegaly, pheochromocytoma, toxic goiter, diabetes mellitus and endometriosis.
Arch Intern Med, 127 (1971), pp. 299-303
[7.]
R.J. Anderson, E.G. Lufkin, G.W. Sizemore, J.A. Carney, S.G. Sep, Y.E. Silling.
Acromegaly and pituitary adenoma with phaeochromocytoma variant of multiple endocrine neoplasia.
Clin Endocrinol (Oxf), 14 (1981), pp. 605-612
[8.]
J.H. Myers, J.J. Eversman.
Acromegaly, hyperparathyroidism and pheochromocitoma in the same patient. A multiple endocrine disorder.
Arch Intern Med, 141 (1981), pp. 1521-1522
[9.]
J. Baughan, C. De Gara, D. Morrish.
A rare association between acromegaly and pheochromocytoma.
Am J Surg, 182 (2001), pp. 185-187
[10.]
G.G. Sleilati, K.T. Kovacs, M. Honasoge.
Acromegaly and pheochromocytoma: report of a rare coexistence.
Endocr Pract, 8 (2002), pp. 54-60
[11.]
S.C. Chandrasekharappa, S.C. Guru, P. Manickam, S.E. Olufemi, F.S. Collins, M.R. Emmert-Buck, et al.
Positional cloning of the gen for multiple endocrine neoplasia type 1.
Science, 276 (1997), pp. 404-407
[12.]
S.C. Guru, P.K. Goldsmith, A.L. Burns, S.J. Marx, A.M. Spiegel, F.S. Collins, et al.
Menin, the product of the MEN1 gene, is a nuclear protein.
Proc Natl Acad Sci U S A, 68 (1998), pp. 820-823
[13.]
S.K. Agarwal, S.C. Guru, C. Heppner, M.R. Erdos, R.M. Collins, S.Y. Park, et al.
Menin interacts with the AP1 transcription factor JunD and represses JunD-activated transcription.
Cell, 96 (1999), pp. 143-152
[14.]
S.K. Agarwal, M.B. Kester, L.V. Debelenko, C. Heppner, M.R. Emmert-Buck, M.C. Skarulis, et al.
Germline mutations of the MEN1 gene in familial multiple endocrine neoplasia type 1 and related states.
Hum Mol Genet, 6 (1997), pp. 1169-1175
[15.]
J.H. Bassett, S.A. Forbes, A.A. Pannett, S.E. Lloyd, P.T. Christie, C. Wooding, et al.
Characterization of mutations in patients with multiple endocrine neoplasia type 1.
Am J Hum Genet, 62 (1998), pp. 232-244
[16.]
K. Oberg, B. Skogseid, B. Eriksson.
Multiple endocrine neoplasia type 1 (MEN-1). Clinical, biochemical and genetical investigations.
Acta Oncol, 28 (1989), pp. 383-387
[17.]
R. Rizzoli, J. Green III, S.J. Marx.
Primary hyperparathyroidism in familial multiple endocrine neoplasia type I. Long-term follow- up of serum calcium levels after parathyroidectomy.
Am J Med, 78 (1985), pp. 467-474
[18.]
S.J. Marx, S.K. Agarwal, M.B. Kester, C. Heppner, Y.S. Kim, M.C. Skarulis, et al.
Multiple endocrine neoplasia type 1: clinical and genetic features of the hereditary endocrine neoplasias.
Recent Prog Hom Res, 54 (1999), pp. 397-438
[19.]
L.M. Mulligan, D.J. Marsh, B.G. Robinson, I. Schuffenecker, J. Zedenius, C.J. Lips, et al.
Genotype-phenotype correlation in multiple endocrine neoplasia type 2: report of the International RET Mutatium Consortium.
J Intern Med, 238 (1995), pp. 343-346
[20.]
L.M. Mulligan, J.B.J. Kwok, C.S. Healey, M.J. Elsdon, C. Eng, E. Gardner, et al.
Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A.
Nature, 363 (1993), pp. 458-460
[21.]
H. Donis-Keller, S. Dou, D. Chi, K.M. Carlson, K. Toshima, T.C. Lairmore, et al.
Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC.
Hum Mol Genet, 2 (1993), pp. 851-856
[22.]
L.M. Mulligan, C. Eng, C.S. Healey, D. Clayton, J.B. Kwok, E. Gardner, et al.
Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC.
Nat Genet, 6 (1994), pp. 70-74
[23.]
W.M. Alberts, J.O. McMeekin, J.M. George.
Mixed multiple endocrine neoplasia syndromes.
JAMA, 244 (1980), pp. 1236-1237
[24.]
S.E. Carty, A.K. Helm, J.A. Amico, M.R. Clarke, T.P. Foley, C.G. Watson, et al.
The variable penetrance and spectrum of manifestations of multiple endocrine neoplasia type 1.
Surgery, 124 (1998), pp. 1106-1113
[25.]
A.P. Dackiw, G.J. Cote, J.B. Fleming, P.N. Schultz, P. Stanford, R. Vassilopoulou-Sellin, et al.
Screening for MEN1 mutations in patients with atypical endocrine neoplasia.
Surgery, 126 (1999), pp. 1097-1103
[26.]
E. Sigl, A. Behmel, T. Henn, G. Wirnsberger, A. Weinshäusl, K. Kaserer, et al.
Cytogenetic and CGH studies of four neuroendocrine tumors and tumor-derived cell lines of a patient with multiple endocrine neoplasia type 1.
Int J Oncol, 15 (1999), pp. 41-51
[27.]
A. Cebrián, S. Ruiz-Llorente, A. Cascón, M. Pollán, J.J. Díez, A. Picó, et al.
Mutational and gross deletion study of the MEN1 gene and correlation with clinical features in Spanish patients.
J Med Genet, 40 (2003), pp. e72
Copyright © 2006. Sociedad Española de Endocrinología y Nutrición
Opciones de artículo
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos